keyword
MENU ▼
Read by QxMD icon Read
search

“Renal medullary carcinoma”

keyword
https://www.readbyqxmd.com/read/30386718/implications-of-programmed-death-ligand-1-positivity-in-non-clear-cell-renal-cell-carcinoma
#1
Juan Chipollini, Mounsif Azizi, Charles C Peyton, Dominic H Tang, Jasreman Dhillon, Philippe E Spiess
The purpose of this study was to assess the prognostic value of programmed death ligand-1 (PD-L1) positivity in a non-clear cell renal cell carcinoma (non-ccRCC) cohort. PD-L1 expression was evaluated by immunohistochemistry (IHC) using formalin-fixed paraffin-embedded (FFPE) specimens from 45 non-ccRCC patients with available tissue. PD-L1 positivity was defined as ≥1% of staining. Histopathological characteristics and oncological outcomes were correlated to PD-L1 expression. Cancer-specific survival (CSS) and recurrence-free survival (RFS) stratified by PD-L1 status were estimated using the Kaplan-Meier method...
2018: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/30372389/non-clear-cell-renal-cell-carcinomas-from-shadow-to-light
#2
Laurence Albiges, Ronan Flippot, Nathalie Rioux-Leclercq, Toni K Choueiri
Non-clear cell renal cell carcinomas (RCCs) account for up to 25% of kidney cancers and encompass distinct diseases with distinct pathologic features, different molecular alterations, and various patterns of response to systemic therapies. Recent advances in molecular biology and large collaborative efforts helped to better define the oncogenic mechanisms at play in papillary, chromophobe, collecting duct, medullary, translocation, and sarcomatoid RCCs. Papillary RCCs are divided into several subsets of tumors characterized by distinct gene expression profiles, chromatin remodeling genes, cell cycle changes, and alterations of the MET pathway...
October 29, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30370813/clear-cell-variant-of-a-follicular-thyroid-tumor-with-uncertain-malignant-potential-a-case-report
#3
C Christofer Juhlin, Robert Bränström, Ivan Shabo, Anders Höög
Follicular neoplasms of the thyroid gland are most often characterized by follicular-patterned thyrocytes with a neutrally stained cytoplasm, while a minority of cases present with oncocytic differentiation (Hürthle cell tumors). Exceedingly rare variants with a clear cell phenotype have also been reported, both as clear cell follicular thyroid adenomas (ccFTAs) and clear cell follicular carcinomas (ccFTCs). We present a patient with a 30-mm lesion in the thyroid isthmus in which the preoperative cytology proposed a follicular tumor...
October 29, 2018: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/30351856/a-review-of-alk-rearranged-renal-cell-carcinomas-with-a-focus-on-clinical-and-pathobiological-aspects
#4
Naoto Kuroda, Emiko Sugawara, Hironori Kusano, Yoshiaki Yuba, Kenji Yorita, Kengo Takeuchi
ALK-rearranged renal cell carcinoma (ALK-RCC) has been recently proposed and incorporated into the recent World Health Organisation Classification of renal tumours as a provisional entity. In this article, we review ALK-RCC with a focus on clinical and pathobiological aspects. Seventeen cases have been described to date. ALK-RCC accounts for less than 1% of all renal tumours. The age of patients ranges from 6 to 61 years with a mean age of 29.6 years. Grossly, the tumour forms were ill-demarcated or well demarcated solid mass in the renal medulla...
2018: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/30341517/robotic-assisted-laparoscopic-nephrectomy-with-vein-thrombectomy-initial-experience-and-outcomes-from-a-single-surgeon
#5
Xin-Wen Ke, Xing Zeng, Xian Wei, Yuan-Qing Shen, Jia-Hua Gan, Ji-Hua Tian, Zhi-Quan Hu
This study was designed to explore the safety and feasibility of robotic-assisted laparoscopic nephrectomy with vein thrombectomy (RAL-NVT) for the treatment of renal cell carcinoma (RCC) with venous tumor thrombus (VTT). Clinical data of 6 patients treated with RAL-NVT between July 2016 and November 2017 in our hospital were retrospectively collected and analyzed. There were 5 males and 1 female with their age ranging from 48 years to 68 years. Five renal tumors were right-sided and one left-sided. Three cases fell in level 0 VTT, one in level I and two in level II...
October 2018: Current medical science
https://www.readbyqxmd.com/read/30328092/kidney-transplantation-in-patients-with-previous-renal-cancer-a-critical-appraisal-of-current-evidence-and-guidelines
#6
REVIEW
Giovanni M Frascà, Fabiana Brigante, Alessandro Volpe, Laura Cosmai, Maurizio Gallieni, Camillo Porta
Due to the increasing occurrence of renal cell carcinoma (RCC) in the general population and the high prevalence of chronic kidney disease among cancer patients, many people with a previous RCC may eventually require renal replacement therapy including kidney transplantation. They should accordingly be evaluated to assess their life expectancy and the risk that the chronic immunosuppressive therapy needed after grafting might impair their long-term outcome. Current guidelines on listing patients for renal transplantation suggest that no delay is required for subjects with small or incidentally discovered RCC, while the recommendations for patients who have been treated for a symptomatic RCC or for those with large or invasive tumours are conflicting...
October 16, 2018: Journal of Nephrology
https://www.readbyqxmd.com/read/30306049/atypical-presentation-of-renal-medullary-carcinoma-a-case-report-and-review-of-the-literature
#7
Ali Al-Daghmin, Malek Gaashan, Hussam Haddad
No abstract text is available yet for this article.
January 2019: Urology Case Reports
https://www.readbyqxmd.com/read/30287223/updated-recommendations-on-the-diagnosis-management-and-clinical-trial-eligibility-criteria-for-patients-with-renal-medullary-carcinoma
#8
Pavlos Msaouel, Andrew L Hong, Elizabeth A Mullen, Michael B Atkins, Cheryl Lyn Walker, Chung-Han Lee, Marcus A Carden, Giannicola Genovese, W Marston Linehan, Priya Rao, Maria J Merino, Howard Grodman, Jeffrey S Dome, Conrad V Fernandez, James I Geller, Andrea B Apolo, Najat C Daw, H Courtney Hodges, Marva Moxey-Mims, Darmood Wei, Donald P Bottaro, Michael Staehler, Jose A Karam, W Kimryn Rathmell, Nizar M Tannir
Renal medullary carcinoma (RMC) is one of the most aggressive renal cell carcinomas. It predominantly afflicts young adults and adolescents with sickle cell trait and other sickle hemoglobinopathies, and is refractory to targeted and antiangiogenic therapies used in patients with clear-cell renal cell carcinoma. Platinum-based cytotoxic chemotherapy is the mainstay for RMC treatment. On the basis of recent advances in the diagnosis, management, and clinical trial development for RMC, a panel of experts met in October 2017 and developed updated consensus recommendations to inform clinicians, researchers, and patients...
September 12, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/30231931/anlotinib-a-novel-multi-targeting-tyrosine-kinase-inhibitor-in-clinical-development
#9
REVIEW
Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, Feng Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Compared to the effect of placebo, it improved both progression-free survival (PFS) and overall survival (OS) in a phase III trial in patients with advanced non-small-cell lung cancer (NSCLC), despite progression of the cancer after two lines of prior treatments. Recently, the China Food and Drug Administration (CFDA) approved single agent anlotinib as a third-line treatment for patients with advanced NSCLC...
September 19, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/30122516/metastatic-renal-medullary-carcinoma-treated-with-immune-checkpoint-inhibitor-case-report-and-literature-review
#10
Rosario F Di Stefano, Consuelo Buttigliero, Emmanuele De Luca, Maria Lucia Reale, Chiara Pisano, Gianmarco Leone, Clizia Zichi, Federica Massa, Matteo Manfredi, Francesca Vignani, Enrico Bollito, Francesco Porpiglia, Massimo Di Maio, Marcello Tucci
No abstract text is available yet for this article.
July 21, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29956055/cabozantinib-induced-serum-creatine-kinase-elevation-and-musculoskeletal-complaints
#11
Sarah E Stump, Young E Whang, Daniel J Crona
Cabozantinib is a multikinase inhibitor approved for the treatment of metastatic medullary thyroid cancer and advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. While associations between serum creatine kinase (CK) elevations and other tyrosine kinase inhibitors used for the treatment of solid malignancies have been previously reported, we report a case of cabozantinib-associated CK elevation that was associated with musculoskeletal complaints by an RCC patient...
December 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29905933/the-classification-of-pediatric-and-young-adult-renal-cell-carcinomas-registered-on-the-children-s-oncology-group-cog-protocol-aren03b2-after-focused-genetic-testing
#12
Mariana M Cajaiba, Lisa M Dyer, James I Geller, Lawrence J Jennings, David George, Dawn Kirschmann, Stephen M Rohan, Nicholas G Cost, Geetika Khanna, Elizabeth A Mullen, Jeffrey S Dome, Conrad V Fernandez, Elizabeth J Perlman
BACKGROUND: Renal cell carcinomas (RCCs) are rare in young patients. Knowledge of their pathologic and molecular spectrum remains limited, and no prospective studies have been performed to date in this population. This study analyzes patients diagnosed with RCC who were prospectively enrolled in the AREN03B2 Children's Oncology Group (COG). The objective was to classify these tumors with the aid of focused genetic testing and to characterize their features. METHODS: All tumors registered as RCC by central review were retrospectively re-reviewed and underwent additional ancillary studies...
August 2018: Cancer
https://www.readbyqxmd.com/read/29848739/renal-cell-carcinoma-unclassified-with-medullary-phenotype-and-synchronous-renal-clear-cell-carcinoma-present-in-a-patient-with-no-sickle-cell-trait-disease-diagnostic-and-therapeutic-challenges
#13
Jenny Z Lai, H Henry Lai, Dengfeng Cao
Renal medullary carcinoma (RMC) is an aggressive high-grade renal cell carcinoma (RCC) associated almost exclusively with sickle cell trait or sickle cell disease. However, RCC with RMC features has rarely been reported in patients with no sickle cell trait or disease. Renal cell carcinoma unclassified with medullary phenotype (RCCU-MP) is a newly-coined term used by an international panel of experts to describe renal cell carcinoma showing morphologic and immunohistochemical features of renal medullary carcinoma in patients without sickle cell trait/disease...
June 2018: Anticancer Research
https://www.readbyqxmd.com/read/29689242/swi-snf-protein-expression-status-in-fumarate-hydratase-deficient-renal-cell-carcinoma-immunohistochemical-analysis-of-32-tumors-from-28-patients
#14
Abbas Agaimy, Mahul B Amin, Anthony J Gill, Bernt Popp, André Reis, Daniel M Berney, Cristina Magi-Galluzzi, Mathilde Sibony, Steven C Smith, Saul Suster, Kiril Trpkov, Ondřej Hes, Arndt Hartmann
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive RCC type, originally described in the setting of hereditary leiomyomatosis and RCC syndrome, which is defined by germline FH gene inactivation. Inactivation of components of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex is involved in renal medullary carcinoma (SMARCB1/INI1 loss), clear cell RCC (PBRM1 loss), and subsets of dedifferentiated RCC of clear cell, chromophobe, and papillary types (loss of different SWI/SNF components)...
July 2018: Human Pathology
https://www.readbyqxmd.com/read/29687244/a-population-pharmacokinetic-model-of-cabozantinib-in-healthy-volunteers-and-patients-with-various-cancer-types
#15
Steven Lacy, Bei Yang, Jace Nielsen, Dale Miles, Linh Nguyen, Matt Hutmacher
PURPOSE: An integrated population pharmacokinetic (popPK) model was developed to describe the pharmacokinetics (PK) of tyrosine kinase inhibitor cabozantinib in healthy volunteers (HVs) and patients with various cancer types and to identify any differences in cabozantinib PK across these populations. METHODS: Plasma concentration data used to develop the popPK model were obtained from nine clinical trials (8072 concentrations from 1534 HVs or patients) of cabozantinib in HVs and patients with renal cell carcinoma (RCC), medullary thyroid carcinoma (MTC), glioblastoma multiforme, castration-resistant prostate cancer, or other advanced malignancies...
June 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29665139/high-grade-infiltrative-adenocarcinomas-of-renal-cell-origin-new-insights-into-classification-morphology-and-molecular-pathogenesis
#16
REVIEW
Jaime A Singh, Chisato Ohe, Steven Christopher Smith
Collecting duct carcinoma was described over 30 years ago as a renal tumor, based in the medullary collecting system, with tubulopapillary morphology, prominent infiltrative growth, and stromal desmoplasia. While diagnostic workup has always emphasized exclusion of upper tract urothelial carcinoma and metastatic adenocarcinoma to the kidney, the molecular era of renal cell carcinoma classification has enabled recognition of and provided tools for diagnosis of new entities in this morphologic differential. In this review, we consider these developments, with emphasis on renal medullary carcinoma, closely related renal cell carcinoma, unclassified with medullary phenotype, and fumarate hydratase-deficient renal cell carcinoma...
May 2018: Pathology International
https://www.readbyqxmd.com/read/29582957/-renal-manifestation-of-autosomal-dominant-polycystic-kidney-disease
#17
REVIEW
Marco Galliani, Silvana Chicca, Elio Vitaliano, Luca Di Lullo, Konstantinos Giannakakis, Antonio Paone
Autosomal dominant polycystic kidney disease affects over 12 million people in the world and is the fourth cause of ESRD. It is the main monogenic kidney disease and causes the progressive formation of cysts leading to renal failure after a few decades. The main manifestations of the disease are observed even at a young age. The early sign of ADPKD is impaired urinary concentrating capacity, due to medullary alteration by cysts, and resistance to vasopressin. These anatomical alterations determine hyperfiltration, altered ammonium transport, nephrolithiasis, and, above all, hypertension even in pediatric age...
March 2018: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/29440190/a-model-linking-sickle-cell-hemoglobinopathies-and-smarcb1-loss-in-renal-medullary-carcinoma
#18
Pavlos Msaouel, Nizar M Tannir, Cheryl Lyn Walker
Renal medullary carcinoma (RMC) is a highly aggressive malignancy that predominantly afflicts young adults and adolescents with sickle hemoglobinopathies. It is characterized by complete loss of expression of the chromatin remodeler and tumor suppressor SMARCB1 Despite therapy, the outcomes of patients with RMC remain very poor, highlighting the need to understand the etiology of this cancer, and develop new diagnostic, preventive, and therapeutic strategies. A key knowledge gap in RMC biology is why sickle hemoglobinopathies predispose to the development of this cancer...
May 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29429165/-clinicopathologic-features-with-collecting-duct-carcinoma-of-kidney-report-of-10-cases
#19
J X Zhou, X R He, G X Song, Z G Zou, L H Wang, R Hu, H X Li
Objective: To study the pathological features, immunophenotypes, differential diagnoses and prognostic parameters of collecting duct carcinoma of the kidney (CDC). Methods: Clinical imaging, histopathology, immunohistochemistry, and survival data of 10 patients at First Affiliated Hospital of Nanjing Medical University from January 2009 to August 2017 were retrospectively analyzed along with a review of literatures. Results: The clinical symptoms of CDC were not specific, and image examinations showed space-occupying mass lesions...
February 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29405994/alk-tpm3-rearrangement-in-adult-renal-cell-carcinoma-report-of-a-new-case-showing-loss-of-chromosome-3-and-literature-review
#20
Yohan Bodokh, Damien Ambrosetti, Valérie Kubiniek, Branwel Tibi, Matthieu Durand, Jean Amiel, Morgane Pertuit, Anne Barlier, Florence Pedeutour
Seven cases of translocation-associated renal cell carcinoma involving ALK (ALK-tRCC) were referenced in the last World Health Organization's classification (2016), in a group of emerging/provisional RCC. The first three cases were pediatric, medullary-based, associated with sickle-cell trait and showed a fusion of ALK with VCL. Thirteen cases have been further described. They displayed clinical, morphological and genomic heterogeneity. Most of them occurred in adults. None of the patients was affected by sickle-cell disease...
February 2018: Cancer Genetics
keyword
keyword
165631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"